Andrew S. Lim, MD

Assistant Professor of Clinical Radiation Oncology

Director of Brachytherapy

Image of Andrew S. Lim, MD
Is this your profile? Click to edit

Overview

Andrew Lim, MD, is a radiation oncologist at USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC, who specializes in today’s most advanced forms of radiation therapy, including interstitial and surface brachytherapy, volumetric modulated arc therapy and stereotactic body radiation therapy.

At USC Norris, he serves as director of brachytherapy, a form of internal radiation therapy in which the radiation source is placed close to the cancer. Dr. Lim routinely treats prostate cancer, gynecologic cancers, sarcomas, skin cancer and metastatic cancers anywhere in the body.

His research interests focus on the development of artificial intelligence (AI) algorithms capable of integrating clinical, biochemical, genomics and radiologic data, with a goal of making personalized, probabilistic medical predictions. Dr. Lim has received several awards for his outstanding research and cancer care.

Away from work, he enjoys creating software tools that help people save time.

Awards

  • University of Alberta: The RJS and Ada Maude Wright Memorial Prize in Radiation Oncology, 2019
     – 2020
  • St. Francis Xavier University: Yogi Joshi Prize For Excellence in Physics, 2008
     – 2009
  • St. Francis Xavier University: Natural Sciences and Engineering Research Council of Canada Award, 2008
     – 2009

Education and Training

  • Western University, London, Ontario — MD — 06/2013 — Medicine
  • University of Alberta, Edmonton, Alberta — FRCPC — 06/2020 — Radiation Oncology
  • University of California, Los Angeles, Los Angeles — 06/2021 — Brachytherapy

Research Keywords

  • Informatics
  • Prostate Cancer
  • Brachytherapy
  • Artificial Intelligence
  • Cervix Cancer

Publications

  • Clostridioides difficile infection and recurrence in cancer patients (CIRCA): A multicentre, international study. Int J Infect Dis. 2025 Apr; 153:107785.. View in PubMed
  • segcsvdWMH: A Convolutional Neural Network-Based Tool for Quantifying White Matter Hyperintensities in Heterogeneous Patient Cohorts. Hum Brain Mapp. 2024 Dec 15; 45(18):e70104.. View in PubMed
  • Clinical and dosimetric outcomes of a 3-fraction high-dose-rate brachytherapy boost for the treatment of locally advanced cervical cancer in a safety net hospital. Brachytherapy. 2025 Jan-Feb; 24(1):162-170.. View in PubMed
  • Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA). J Alzheimers Dis. 2024 12; 102(3):535-561.. View in PubMed
  • Updated consensus guidelines for management of moderate-to-severe atopic dermatitis in Singapore: Integrating biologics, Janus kinase inhibitors and conventional therapies. Ann Acad Med Singap. 2024 Nov 29; 53(11):670-682.. View in PubMed
  • Retinal microvascular phenotypes can track small vessel disease burden and CPAP treatment effectiveness in obstructive sleep apnea. J Cereb Blood Flow Metab. 2025 04; 45(4):690-702.. View in PubMed
  • Pioneering a multi-phase framework to harmonize self-reported sleep data across cohorts. Sleep. 2024 09 09; 47(9).. View in PubMed
  • Dosimetric characterization for GRID collimator-based spatially fractionated radiation therapy: Dosimetric parameter acquisition and machine interchangeability investigation. J Appl Clin Med Phys. 2024 Aug; 25(8):e14410.. View in PubMed
  • A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome. Bone Marrow Transplant. 2024 Jul; 59(7):1025-1027.. View in PubMed
  • Critical care delivery across health care systems in low-income and low-middle-income country settings: A systematic review. J Glob Health. 2023 Dec 01; 13:04141.. View in PubMed